CL vs URGN · P/E 34, rev $10.69B vs rev $123.4M
Colgate-Palmolive Company (CL) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported CL revenue for 2026-06-30 was $10.69B. Net income was $1.34B. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
CL currently screens at market cap $70.88B and trailing P/E 34.3. URGN currently screens at market cap $1.61B.
Not investment advice. Open the CL and URGN stock pages for the full models.
Not investment advice.